Neurotech International Valuation

Q: What is the Fair Price of NTI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NTI (A$0.07) is trading above our estimate of [[fair value]] (A$0.04)

Is NTI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NTI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NTI (A$0.07) is trading above our estimate of fair value (A$0.04)

Significantly Below Fair Value: NTI is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NTI?

Key metric: As NTI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NTI. This is calculated by dividing NTI's market cap by their current revenue.
What is NTI's PS Ratio?
PS Ratio	22.5x
Sales	AU$3.18m
Market Cap	AU$71.39m

NTI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	18.8x
Enterprise Value/EBITDA	-11.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does NTI's PS Ratio compare to its peers?

The above table shows the PS ratio for NTI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.1x
CVB CurveBeam AI	5.8x	45.9%	AU$37.7m
MX1 Micro-X	2.3x	38.2%	AU$34.3m
EMV EMVision Medical Devices	14.7x	n/a	AU$164.6m
AHC Austco Healthcare	1.6x	n/a	AU$91.0m
NTI Neurotech International	22.5x	44.7%	AU$71.4m

Price-To-Sales vs Peers: NTI is expensive based on its Price-To-Sales Ratio (22.5x) compared to the peer average (6.1x).

Price to Sales Ratio vs Industry

How does NTI's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
SDI SDI	1.2x	5.4%	US$83.19m
SOM SomnoMed	0.9x	9.0%	US$55.32m
CMP Compumedics	1x	n/a	US$30.96m
NXS Next Science	1.1x	30.6%	US$26.50m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: NTI is expensive based on its Price-To-Sales Ratio (22.5x) compared to the Australian Medical Equipment industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is NTI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NTI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	22.5x
Fair PS Ratio	23.7x

Price-To-Sales vs Fair Ratio: NTI is good value based on its Price-To-Sales Ratio (22.5x) compared to the estimated Fair Price-To-Sales Ratio (23.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Doctor Care Anywhere Group

AU$23.8m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.066

1.5%

40.4%

SDI

AU$128.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.10

7.4%

45.0%

CardieX

AU$29.4m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.099

-13.9%

n/a